Dr Kimberly Jill Hunziker, D,C,, LAC | |
1086 Baxter Ln E, Bozeman, MT 59718-9782 | |
(406) 579-1991 | |
Not Available |
Full Name | Dr Kimberly Jill Hunziker |
---|---|
Gender | Female |
Speciality | Contractor |
Location | 1086 Baxter Ln E, Bozeman, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1467986083 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
111N00000X | Chiropractor | 780 (Montana) | Secondary |
171W00000X | Contractor | 50238 (Montana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Kimberly Jill Hunziker, D,C,, LAC 1086 Baxter Ln E, Bozeman, MT 59718-9782 Ph: (406) 579-1991 | Dr Kimberly Jill Hunziker, D,C,, LAC 1086 Baxter Ln E, Bozeman, MT 59718-9782 Ph: (406) 579-1991 |
News Archive
Now researchers at the Monell Chemical Senses Center report in the current issue of the journal Pain that the analgesic efficacy of sweet taste is influenced both by how much a child likes sweet taste and by the child's weight status.
Soy isoflavone supplements did not decrease breast cancer cell proliferation in a randomized clinical trial, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
A program by Stony Brook Children's Hospital that involves the use of trained community health workers on child immunization reveals that home intervention and education improves vaccine/immunization rates in at-risk children, including those living in poverty.
Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.
Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.
› Verified 2 days ago